Krystal Biotech Closes IPO

9/22/17

PITTSBURGH, Sept. 22, 2017 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (NASDAQ:KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases, today announced the closing of its initial public offering of 4,554,000 shares of common stock at a price to the public of $10.00 per share, which includes 594,000 shares of common stock issued upon full exercise by the underwriter of their option to purchase additional shares. Aggregate gross proceeds to Krystal were $45,540,000, before underwriting discounts, commissions and expenses. Krystal’s common stock is traded on the NASDAQ Capital Market under the ticker symbol “KRYS.”

Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE American:LTS), acted as sole book-running manager in connection with the offering.

ABOUT KRYSTAL BIOTECH

Krystal Biotech, Inc. (NASDAQ:KRYS) is a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases. For more information, please visit http://www.krystalbio.com.

It's on us. Share your news here.

Submit your stories and articles to citybizlist today.